Abstract:The human gut is inhabited by a multitude of bacteria, yeasts, and viruses. A dynamic balance among these microorganisms is associated with the well-being of the human being, and a large body of evidence supports a role of dysbiosis in the pathogenesis of several diseases. Given the importance of the gut microbiota in the preservation of human health, probiotics, prebiotics, synbiotics, and postbiotics have been classically used as strategies to modulate the gut microbiota and achieve beneficial effects for the host. Nonetheless, several molecules not typically included in these categories have demonstrated a role in restoring the equilibrium among the components of the gut microbiota. Among these, rifaximin, as well as other antimicrobial drugs, such as triclosan, or natural compounds (including evodiamine and polyphenols) have common pleiotropic characteristics. On one hand, they suppress the growth of dangerous bacteria while promoting beneficial bacteria in the gut microbiota. On the other hand, they contribute to the regulation of the immune response in the case of dysbiosis by directly influencing the immune system and epithelial cells or by inducing the gut bacteria to produce immune-modulatory compounds, such as short-chain fatty acids. Fecal microbiota transplantation (FMT) has also been investigated as a procedure to restore the equilibrium of the gut microbiota and has shown benefits in many diseases, including inflammatory bowel disease, chronic liver disorders, and extraintestinal autoimmune conditions. One of the most significant limits of the current techniques used to modulate the gut microbiota is the lack of tools that can precisely modulate specific members of complex microbial communities. Novel approaches, including the use of engineered probiotic bacteria or bacteriophage-based therapy, have recently appeared as promising strategies to provide targeted and tailored therapeutic modulation of the gut microbiota, but their role in clinical practice has yet to be clarified. The aim of this review is to discuss the most recently introduced innovations in the field of therapeutic microbiome modulation.

Drug and gut microbe relationships: Moving beyond antibiotics

Integrating the gut microbiome and pharmacology

Interplays between drugs and the gut microbiome

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response

Interaction between drugs and the gut microbiome

Human Gut Microbiota and Drug Metabolism

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era

Small molecules in the big picture of gut microbiome-host cross-talk

The role of the human gut microbiota in colonization and infection with multidrug-resistant bacteria

Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine

Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities

Emergence of community behaviors in the gut microbiota upon drug treatment

Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota

A critical need for 'gut neutrality': mitigating adverse drug–microbiome interactions

Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy

The metabolic effect of gut microbiota on drugs

High-throughput transcriptomics of 409 bacteria–drug pairs reveals drivers of gut microbiota perturbation

Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus